Changes of circulating micro-RNAs in response to treatment with teriparatide or denosumab in postmenopausal osteoporosis.

Changes of circulating micro-RNAs in response to treatment with teriparatide or denosumab in postmenopausal osteoporosis.

J Clin Endocrinol Metab. 2017 Dec 22;:

Authors: Anastasilakis AD, Makras P, Pikilidou M, Tournis S, Makris K, Bisbinas I, Tsave O, Yovos JG, Yavropoulou MP

Abstract
Context: Expression of microRNAs (miRs) related to bone metabolism in the serum maybe affected by anti-osteoporotic treatment.
Objective: To investigate the effect of two anti-osteoporotic agents with opposite effects on bone metabolism on microRNA expression profile in the serum.
Design: Observational, open label, non-randomized clinical trial.
Setting: The outpatient clinics for Metabolic Bone Diseases of 424 General Military Hospital, Thessaloniki, Greece.
Patients and Interventions: Postmenopausal women with low bone mass were treated with either teriparatide (n=30) or denosumab (n=30) for 12 months.
Main outcome measures: Changes in the serum expression of selected miRs linked to bone metabolism at 3 and 12 months of treatment. Secondary measurements: associations of measured miRs with changes in bone mineral density (BMD) at 12 months and the bone turnover markers (BTM) C-terminal telopeptide of type I collagen (β-CTX) and procollagen type I N-terminal propeptide (P1NP) at 3 and 12 months.
Results: We found significantly decreased therelative expression of miR-33-3p at 3 months (p=0.03) and of miR-133a at 12 months (p=0.042) of teriparatide treatment. BMD values at 12 months of teriparatide treatment were significantly and inversely correlated with miR-124-3p expression at 3 months (p=0.008). Relative expression of miR-24-3p and miR-27a was correlated with changes in BTM during teriparatide treatment and of miR-21-5p, miR-23a-3p, miR-26a-5p, miR-27a, miR-222-5p and miR-335-5p with changes in BTM during denosumab treatment.
Conclusions: Circulating miRs are differentially affected by treatment with teriparatide and denosumab. Teriparatide affects the relative expression of mirRs related to the expression of RUNX-2 (miR-33) and DKK-1 gene (miR-133).

PMID: 29309589 [PubMed - as supplied by publisher]

http://ift.tt/2CK5o2j